

<p>According to the Paperwork Reduction Act of 1995, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is 0579-0036. The time required to complete this information collection is estimated to average .5 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.</p>		<p><b>OMB APPROVED</b> 0579-0036</p>
		<p>Interagency Report Control No. 0180-DOA-AN</p>
		<p>Fiscal year: 2021-2022</p>
<p align="center"><b>UNITED STATES DEPARTMENT OF AGRICULTURE</b> <b>ANIMAL AND PLANT HEALTH INSPECTION SERVICE</b></p> <p align="center"><b>Annual Report of Research Facility</b> <b>Column E Explanation</b> (TYPE OR PRINT)</p>		
<p>This information is required by law (7 U.S.C. 2143 and 9 C.F.R. §2.36). Failure to report according to the regulations can result in an order to cease and desist.</p>		
<p><b>1. REGISTRATION NUMBER</b></p> <p align="center">322137</p>	<p><b>2. Research Facility Headquarters address</b> BTS Research, 9990 Mesa Rim Road, Suite 100</p>	
<p><b>3. Number of animals used in the study.</b></p> <p align="center">14</p>	<p><b>4. Species (common name) of animals used in the study.</b> Guinea Pig</p>	
<p><b>5. Explain the procedure producing pain and distress.</b> Guinea Pigs were used in a chemically induced heart failure model, which is being used to treat humans in Cardiovascular Research.</p>		
<p><b>6. Provide the scientific justification for not providing the appropriate anesthetics, analgesics, or tranquilizing drugs during procedures where the animal experienced accompanying pain or distress greater than momentary or slight.</b> Compounds, including anesthetics or analgesics, or tranquilizing drugs, may interfere with the histological progression of heart disease will prevent understanding and documentation of disease progression in this study for heart disease. Clinical signs of disease progression are one of the data points of use to determining therapeutic efficacy from this study.</p>		
<p><b>7. What, if any, Federal regulations require this procedure? Cite the agency, the Code of Federal Regulations (CFR) title number, and the specific section number (e.g., APHIS, 9 CFR 113, 102):</b></p> <p>NA</p>		
<p><b>Agency</b></p>		<p><b>CFR</b></p>